CB CD34⁺ cells with up-regulated hTERT expression contained short-term multipotent SRCs. Sorted dGFP⁺, GFP⁺, and mock-transduced cells were transplanted into NOD/SCID B2m^–/– or NOD/SCID mice via tail-vein injections at 1.0 × 10⁵ cells per animal. Human-cell engraftment in mouse bone marrow was assessed 6 weeks later. (A) The gating for assessing human-cell engraftment (hu-CD45⁺ cells), myeloid differentiation (CD33/15⁺ cells), lymphoid differentiation (CD19⁺ cells), and regeneration of primitive CD34⁺ cells from a representative animal is shown. (B) The percentages of hu-CD45⁺ cells in the bone marrow of primary NOD/SCID B2m^–/– mice recipients following transplantation of dGFP⁺, GFP⁺, or mock-transduced cells are shown. (C) The percentages of hu-CD45⁺ cells in the bone marrow of NOD/SCID mice recipients following transplantation of dGFP⁺, GFP⁺, or mock-transduced cells are shown. (D) The percentages of hu-CD45⁺ cells in the bone marrow of secondary NOD/SCIDB2m^–/– recipients following transplantation with total bone marrow cells from primary NOD/SCIDB2m^–/– mice recipients are shown. In panels B-D, each dot represents one mouse and each figure is a summary of 2 independent experiments. The horizontal bars show the average levels of hu-CD45⁺ cells.